Form 4: Dyne Therapeutics Director Jason Rhodes Acquires Stock Options
SEC Form 4 Filing
Director Jason Rhodes acquired 25,133 stock options in Dyne Therapeutics on May 22, 2024, with vesting scheduled for May 22, 2025, or the date of the 2025 Annual Meeting of Stockholders.
Summary
- On May 22, 2024, Jason P Rhodes, a director of Dyne Therapeutics, acquired 25,133 stock options.
- The exercise price of these options is $31.53.
- The options vest fully on the earlier of May 22, 2025, or the date of the Issuer's 2025 Annual Meeting of Stockholders, contingent upon continued service.
- Rhodes is a member of Atlas Venture Associates XI, LLC and is obligated to transfer any economic benefit from the sale of shares from exercising the option to Atlas Venture Life Science Advisors, LLC.
- Rhodes disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a stock option grant. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the holdings and transactions of company insiders. It is a standard practice for directors and officers of publicly traded companies.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
- The vesting schedule incentivizes the director to remain with the company.
Key Dates
| Date | Description |
|---|---|
| 05/22/2024 | Date of transaction: Jason Rhodes acquired 25,133 stock options. |
| 05/22/2025 | Vesting date of the stock options, or the date of the Issuer's 2025 Annual Meeting of Stockholders, whichever is earlier. |
| 05/21/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.